Business
Rallybio Reports First Quarter 2025 Financial Results and Provides Business Updates
NEW HAVEN, Conn., May 08, 2025--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today reported first quarter financial results for the period ended March 31, 2025, and provided an update on recent company developments.
About this update from Rallybio Corporation
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":244,"url":"https://media.zenfs.com/en/business-wire.com/1cd75bd22489ac94790bf384ea3b702e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/zJvButIO5Sw_bX4t_bpo0Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4ODtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/1cd75bd22489ac94790bf384ea3b702e","width":480,"height":244}},"lazy":false},{"type":"text","content":"– On Track to Initiate Dosing in RLYB116 Confirmatory PK/PD Study in 2Q 2025, with Multiple Data Readouts Anticipated in 2H 2025 –","length":130,"tagName":"p","attribs":{}},{"type":"text","content":"– $54.5 Million in Cash, Cash Equivalents, and Marketable Securities as of March 31, 2025 Provides Runway into 1H 2027 –","length":120,"tagName":"p","attribs":{}},{"type":"text","content":"NEW HAVEN, Conn., May 08, 2025--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today reported first quarter financial results for the period ended March 31, 2025, and provided an update on recent company developments.","length":370,"tagName":"p"},{"type":"text","content":""We are focused on advancing RLYB116 into a confirmatory pharmacokinetic/pharmacodynamic study this quarter, and believe that data from this study will demonstrate RLYB116’s potential to be a best-in-class therapeutic for patients with complement-driven diseases," said Stephen Uden, M.D., Chief Executive Officer of Rallybio. "Leveraging our team’s deep expertise in the complement field, we are well-positioned to maximize RLYB116’s transformative potential across multiple billion-dollar market opportunities. Additionally, we believe significant value resides within our preclinical pipeline, which includes REV102 and RLYB332. By advancing our innovative pipeline, we are committed to creating exceptional value for our shareholders while delivering life-changing therapies to patients who need them most."","length":831,"tagName":"p"},{"type":"text","content":"Recent Business Highlights and Upcoming Milestones:","length":51,"tagName":"p"},{"type":"text","content":"RLYB116 Program","length":15,"tagName":"p"},{"type":"list...